A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Botanix Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Hyperhidrosis

Treatments

Drug: BBI-4000

Study type

Interventional

Funder types

Industry

Identifiers

NCT02058264

BBI-4000-CL-101

Details and patient eligibility

About

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and treatment effect of BBI-4000 when topically applied to subjects with axillary hyperhidrosis.

Full description

This is a randomized, vehicle controlled, double blind study in subjects with axillary hyperhidrosis designed to assess the safety, tolerability and the effect on sweat production of topically applied BBI-4000 for 14 days.

Safety will be assessed though vital signs, physical exam, adverse events, local skin reactions and laboratory tests (blood chemistry and hematology).

Efficacy will be assessed though the gravimetrically measured sweat production and the Hyperhidrosis Disease Severity Score (HDSS).

Pharmacokinetic information will also be collected.

Enrollment

18 patients

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or Female subjects from 18 to 45 years of age in good general health.
Primary axillary hyperhidrosis of at least 6 months duration.
Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.
Gravimetric test at baseline indicating at least 100mg of axillary sweat production in a 5 min period.
Use of a medically appropriate contraceptive method.

Exclusion criteria

Prior axillary use of botulinum toxin within 2 years of study entry.
Prior iontophoresis treatment for axillary hyperhidrosis within 12 weeks of study entry.
Prior surgical procedures for hyperhidrosis or surgical procedures in the axillary areas for any reason.
Use of anticholinergic treatment, beta-blocker, alpha-adrenergic or other prescription treatment for hyperhidrosis.
History of diabetes mellitus, thyroid disease, malignancy, glaucoma, intestinal obstructive or motility disease, obstructive uropathy, myasthenia gravis, prostate hypertrophy, neurological conditions or cardiac abnormalities.
Known condition that may cause hyperhidrosis.
Use of an investigational drug within 30 days prior to entry into this study.